|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61P 35/02 | (2006.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 31/475 | (2006.01) |
| (11) | Number of the document | 3110440 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15755939.4 |
| Date of filing the European patent application | 2015-02-25 | |
| (97) | Date of publication of the European application | 2017-01-04 |
| (45) | Date of publication and mention of the grant of the patent | 2023-08-23 |
| (46) | Date of publication of the claims translation | 2023-10-25 |
| (86) | Number | PCT/US2015/017425 |
| Date | 2015-02-25 |
| (87) | Number | WO 2015/130732 |
| Date | 2015-09-03 |
| (30) | Number | Date | Country code |
| 201461946008 P | 2014-02-28 | US | |
| 201462004540 P | 2014-05-29 | US |
| (72) |
DOSHI, Parul , US
|
| (73) |
Janssen Biotech, Inc. ,
800/850 Ridgeview Drive, Horsham, PA 19044,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-CD38 antikūnai, skirti ūminės limfoblastinės leukemijos gydymui |
| ANTI-CD38 ANTIBODIES FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA |
| Payment date | Validity (years) | Amount | |
| 2025-01-20 | 11 | 289.00 EUR |
| 2026-02-25 |